These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20462647)

  • 41. Growing importance of capitation in Switzerland.
    Beck K
    Health Care Manag Sci; 2000 Feb; 3(2):111-9. PubMed ID: 10780279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Direct versus indirect standardization in risk adjustment.
    Schokkaert E; Van de Voorde C
    J Health Econ; 2009 Mar; 28(2):361-74. PubMed ID: 19111360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High cost pool or high cost groups-How to handle high(est) cost cases in a risk adjustment mechanism?
    Schillo S; Lux G; Wasem J; Buchner F
    Health Policy; 2016 Feb; 120(2):141-7. PubMed ID: 26806676
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk adjustment and the trade-off between efficiency and risk selection: an application of the theory of fair compensation.
    Schokkaert E; Dhaene G; Van de Voorde C
    Health Econ; 1998 Aug; 7(5):465-80. PubMed ID: 9753380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Shifted deductibles for high risks: more effective in reducing moral hazard than traditional deductibles.
    van Kleef RC; van de Ven WP; van Vliet RC
    J Health Econ; 2009 Jan; 28(1):198-209. PubMed ID: 18996607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Community rating in the absence of risk equalisation: lessons from the Irish private health insurance market.
    Turner B; Shinnick E
    Health Econ Policy Law; 2013 Apr; 8(2):209-24. PubMed ID: 22717020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mandatory high-risk pooling: an approach to reducing incentives for cream skimming.
    van Barneveld EM; van Vliet RC; van de Ven WP
    Inquiry; 1996; 33(2):133-43. PubMed ID: 8675277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Legal rules and industry norms: the impact of laws restricting health insurers' use of genetic information.
    Hall MA
    Jurimetrics; 1999; 40(1):93-122. PubMed ID: 12737178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. German risk structure compensation: enhancing equity and effectiveness.
    Files A; Murray M
    Inquiry; 1995; 32(3):300-9. PubMed ID: 7591043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The 2018 risk-adjustment reform in the Czech Republic: Introducing Pharmacy-based Cost Groups and strengthening reinsurance.
    Bryndová L; Hroboň P; Tulejová H
    Health Policy; 2019 Aug; 123(8):700-705. PubMed ID: 31196570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk selection and complementary health insurance: the Swiss approach.
    Kifmann M
    Int J Health Care Finance Econ; 2006 Jun; 6(2):151-70. PubMed ID: 16783507
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The new risk adjustment formula in Germany: implementation and first experiences.
    Buchner F; Goepffarth D; Wasem J
    Health Policy; 2013 Mar; 109(3):253-62. PubMed ID: 23276484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Switching insurer in the Irish voluntary health insurance market: determinants, incentives, and risk equalization.
    Keegan C; Teljeur C; Turner B; Thomas S
    Eur J Health Econ; 2016 Sep; 17(7):823-31. PubMed ID: 26359243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Imperfect risk adjustment, risk preferences, and sorting in competitive health insurance markets.
    Layton TJ
    J Health Econ; 2017 Dec; 56():259-280. PubMed ID: 29248056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heteroscedasticity of residual spending after risk equalization: a potential source of selection incentives in health insurance markets with premium regulation.
    Oskam M; van Kleef RC; Douven R
    Eur J Health Econ; 2024 Apr; 25(3):379-396. PubMed ID: 37162689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outpatient encounter data for risk adjustment--a view from Europe: comments on Welch.
    Smith PC
    J Ambul Care Manage; 2002 Jul; 25(3):23-5. PubMed ID: 12141015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cream-skimming in deregulated social health insurance: evidence from Switzerland.
    Beck K; Zweifel P
    Dev Health Econ Public Policy; 1998; 6():211-27. PubMed ID: 10662405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improving risk equalization for individuals with persistently high costs: Experiences from the Netherlands.
    Eijkenaar F; van Vliet RCJA
    Health Policy; 2017 Nov; 121(11):1169-1176. PubMed ID: 28942090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Using Quantile and Asymmetric Least Squares Regression for Optimal Risk Adjustment.
    Lorenz N
    Health Econ; 2017 Jun; 26(6):724-742. PubMed ID: 27291046
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Health-adjusted premium subsidies in the Netherlands.
    van de Ven WP; van Vliet RC; Lamers LM
    Health Aff (Millwood); 2004; 23(3):45-55. PubMed ID: 15160802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.